This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Soltamox, Liquid Version Of Tamoxifen Citrate (Photo: Business Wire)

DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it has launched Soltamox® (tamoxifen citrate) oral solution in the United States. Soltamox is a new treatment option for breast cancer patients who are prescribed tamoxifen therapy. DARA has exclusive U.S. rights to Soltamox from Rosemont Pharmaceuticals, Ltd, UK.
Soltamox, liquid version of tamoxifen citrate (Photo: Business Wire)

Soltamox, liquid version of tamoxifen citrate (Photo: Business Wire)

Since its approval in 1977, tamoxifen has been used to treat millions of women and men diagnosed with hormone-receptor-positive breast cancer. Treatment with tamoxifen lowers the risk of breast cancer recurrence, breast cancer in the opposite breast, and death from breast cancer.

Breast cancer remains a serious medical issue with over 2.6 million patients in the U.S. with a history of the disease and an estimated 240,000 new patients diagnosed each year. Breast cancer is the leading cause of cancer death in women between the ages of 15 and 54, and the second-leading cause of cancer death in women 55 to 74.

Helping patients who may have difficulty swallowing pills

Prior to DARA's launch of Soltamox, tamoxifen was only available in the U.S. as a solid oral tablet. Difficulty swallowing pills is not uncommon and certain breast cancer patients may experience such difficulties as a result of surgical, pharmaceutical, radiation, or chemotherapy treatments. Discomfort or problems when swallowing may lead patients to miss doses or discontinue their treatment. Soltamox provides an oral liquid medication option that may provide an opportunity for patients to remain compliant with prescribed tamoxifen therapy.

DARA CEO, David J. Drutz, MD, stated, “Compliance and adherence to prescribed tamoxifen therapy is a critical issue in patient care and may affect treatment outcomes. Soltamox provides a unique treatment option for those patients with swallowing difficulties or who simply prefer an oral liquid over tablets or pills. We are excited to provide breast cancer patients an alternative to their current tamoxifen formulation that may help them achieve long-term treatment success.” Dr. Drutz added, "The launch of Soltamox represents a major milestone for DARA in our quest to become a premier provider of important oncology treatment and supportive care products."

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.69 -0.59%
FB $119.49 1.43%
GOOG $711.11 1.40%
TSLA $214.93 1.61%
YHOO $37.23 0.79%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs